Ascenta Therapeutics: Clinical Trials

8 completed, 3 terminated, 1 withdrawn. 10 Phase 2, 6 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 8, Terminated 2
Phase 1	6	Completed 3, Terminated 2, Withdrawn 1

Follow Ascenta Therapeutics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) AT-406 in combination with daunorubicin and cytarabine - Acute Myelogenous Leukemia (AML)	Phase 1	Terminated	Ascenta Therapeutics	29	2011-02-01	2013-01-23
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Tarceva plus AT-101 - Carcinoma, Non Small Cell Lung	Phase 1	Withdrawn	University of Alabama at Birmingham		2010-02-01	2015-05-08
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations oral erlotinib and pulsed doses of oral AT-101 - Lung Cancer	Phase 2	Terminated	Memorial Sloan Kettering Cancer Center	6	2009-09-01	2015-11-20
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel - Hormone Refractory Prostate Cancer	Phase 2	Completed	Ascenta Therapeutics	220	2007-10-01	2010-11-09
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer AT-101 and docetaxel, placebo and docetaxel - Non-small Cell Lung Cancer	Phase 2	Completed	Ascenta Therapeutics	106	2007-09-01	2010-08-27
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer AT-101 - Locally Advanced Esophageal or GE Junction Cancer	Phase 1 / Phase 2	Terminated	Ascenta Therapeutics	13	2007-08-01	2013-01-04
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer AT-101, topotecan - Small Cell Lung Cancer	Phase 1 / Phase 2	Completed	Ascenta Therapeutics	36	2006-11-01	2010-08-24
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma AT-101, Rituximab - Follicular Lymphoma	Phase 2	Completed	Ascenta Therapeutics	23	2006-10-01	2010-08-27
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC AT-101 - Prostate Cancer	Phase 1 / Phase 2	Completed	Ascenta Therapeutics	76	2006-02-01	2011-06-29
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia AT-101 - Chronic Lymphocytic Leukemia	Phase 2	Completed	Ascenta Therapeutics	19	2006-01-01	2010-08-13
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer AT-101 - Hormone Refractory Prostate Cancer	Phase 1 / Phase 2	Completed	Ascenta Therapeutics	27	2005-12-01	2010-08-24
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies AT-101 - Follicular Lymphoma, Diffuse Large Cell Lymphoma	Phase 2	Completed	Ascenta Therapeutics	50	2005-11-01	2011-06-29

Conditions studied

Neoplasms (6)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma (2)  ·  Lymphoma, Follicular (2)  ·  Prostatic Neoplasms (2)  ·  Disease (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Neoplasm Metastasis (1)  ·  Small Cell Lung Carcinoma (1)

Interventions

gossypol acetic acid (10)  ·  Docetaxel (2)  ·  Erlotinib Hydrochloride (2)  ·  Cytarabine (1)  ·  Daunorubicin (1)  ·  N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Topotecan (1)

Countries

United States (11)  ·  Russia (3)  ·  Ukraine (2)

Top investigators

Lance Leopold, MD (8)  ·  Francisco Robert, M.D. (1)  ·  J. Mel Sorensen, MD (1)  ·  Naiyer Rizvi, MD (1)  ·  Thomas Kipps, MD, PhD (1)

Results publications

PMID 21982118